Generic Name and Formulations:
Methylphenidate HCl 20mg; ext-rel tabs; dye-free; contains sucrose.
Adults and Children:
Swallow whole. <6yrs: not established. ≥6yrs: may use Metadate ER tabs in place of immediate-release products when the 8-hour dose of Metadate ER corresponds to the titrated 8-hour dose of immediate-release product; max 60mg daily.
Indications for METADATE ER:
Adults and Children:
Swallow whole. <6yrs: not recommended. ≥6yrs: may use Metadate ER tabs in place of immediate-release products when the 8-hour dose of Metadate ER corresponds to the titrated 8-hour dose of immediate-release product; max 60mg daily.
During or within 14 days of MAOIs. Marked anxiety, tension, agitation. Severe hypertension. Angina. Cardiac arrhythmias. Heart failure. Recent MI. Hyperthyroidism. Thyrotoxicosis. Glaucoma. Surgery. History of tics or Tourette's syndrome in patient or family.
History of drug dependence or alcoholism; monitor. Structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems: not recommended. Pre-existing hypertension. Assess cardiovascular status. Psychosis. Bipolar disorder. Mania. Monitor for worsening of aggressive behavior or hostility. Seizure disorders; discontinue if occur. Risk of peripheral vasculopathy, including Raynaud's phenomenon; monitor for digital changes. Monitor growth, HR, BP, CBC, differential, and platelet counts. Interrupt therapy if growth suppression occurs. Reduce dose or discontinue if paradoxical worsening of symptoms occur. Re-evaluate periodically. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Avoid alcohol. Caution with pressor agents. May potentiate anticonvulsants (eg, phenobarbital, phenytoin, primidone), oral anticoagulants, tricyclics, SSRIs, phenylbutazone. May be affected by agents that alter urinary pH.
Headache, anorexia, abdominal pain, dizziness, rash, insomnia, nervousness, blood dyscrasias, weight loss, nausea, dyskinesias, tachycardia, arrhythmias; priapism, Tourette's syndrome, toxic psychosis, seizures, hypertension, visual disturbances.
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
- Romosozumab: Effective in Men With Osteoporosis
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- NT-proBNP May Predict Cardiovascular Outcomes in Type 2 Diabetes
- Placebo Effect of Various Female Sexual Dysfunction Drug Txs Assessed
- Link Between Oral Diabetes Medications and Bullous Pemphigoid
- Calcium Channel Blocker May Benefit Patients With Type 1 Diabetes
- β-Cell Function in Youth With Impaired Glucose Tolerance, T2D